Logo Sangui

pdf_downloadicon
Downloads as PDF-File
20210510-news-EN.pdf
20210210-news-EN.pdf
20201116-news-EN.pdf
201001-news-EN.pdf
20200526-news-EN.pdf
20200514-news-EN.pdf
200214-news-EN.pdf
191223-news-EN.pdf
191204-news-EN.pdf
191118_news_EN.pdf
191009-news-EN.pdf
190514-news-EN.pdf
190306-news-EN.pdf
190214-news-EN.pdf
181115-news_EN.pdf
181002-news_EN.pdf
180725_news_EN.pdf
180703_news_EN.pdf
180522_news_EN.pdf
180504_news_EN.pdf
180214_news_EN.pdf
180119_news_EN.pdf
171121_news_EN.pdf
171110_news_EN.pdf
171023_news_EN.pdf
170712_news_EN.pdf
170224_Financials_EN.pdf
170112_Financials_EN.pdf
161221_Sales_EN.pdf
161122 financials_EN.pdf
161101 sales_agreements_EN.pdf
161014 news_EN.pdf
160929 news_EN.pdf
160606 news_EN.pdf
160201 preliminary figures_EN.pdf
151028 Preliminary 16Q1_EN.pdf
150929 Financials FY15_EN.pdf
150827 Financials FY15_EN.pdf
150626 Preliminary Prospectus.pdf
150602 EWMA_EN.pdf
150515 Financials 15Q3_EN.pdf
150512 Financing_EN.pdf
150318 Preclinical Results EN.pdf
150212 Financials 15Q2_EN.pdf
150203 Eastern Europe_EN.pdf
150128 ShareholderLetter_EN.pdf
150128 Preliminary Q2 Revenues_EN.pdf
141113 Financials 15Q1_EN.pdf
141111 Preclinical Results EN.pdf
141106 OTCQB EN.pdf
141103 Silanes EN.pdf
141007 Q1 Revenues_EN.pdf
140925 Financials FY14_EN.pdf
140806 ARDS_trials_EN2.pdf
140731 Wound Treatment Patent_EN.pdf
140729 Preliminary Q4 Revenues_EN.pdf
140526 woundspray_EN.pdf
140515 Financials 14Q3_EN.pdf
140425 start in vitro tests_EN.pdf
140214 Financials 14Q2_EN.pdf
140114 Shareholder Letter_en.pdf
131205 Three Partners_EN.pdf
131115 infirst_EN.pdf
131106 Financials 14Q1_EN.pdf
131015 ECCPS_EN.pdf
131008 Scherrer_EN.pdf
130927 Financials FY13_EN.pdf
130923 Colpharma EN.pdf
130917 FEA Award_EN.pdf
130910 Ramma_EN.pdf
130904 Hb Patent EN.pdf
130813 Wound Treatment Patent_EN.pdf
130716 MEDiLAB_EN.pdf
130521 PM 9M figures_E.pdf
130422 BiologiQ en.pdf
130409 Additiv_E.pdf
130322 Notiz Berlin_E.pdf
130215 Half year figures_E.pdf
130205 Prague study_published_E.pdf
121221 Mexiko Sales_E.pdf
121212 Prague study_E.pdf
121017 Pegylation patent granted E.pdf
120827 PM Complementing Agreement E.pdf
120813 PM 100 days E.pdf
news147_en.pdf
news146_en.pdf
news145_en.pdf
news144_en.pdf
news143_en.pdf
news142_en.pdf
news141_en.pdf
news140_en.pdf

Media Releases

Sangui BioTech:
  • Significant increase in sales in the first nine months
  • Reduction of operating loss

Hamburg, May, 10 2021:
In the first nine month of fiscal year 2021 (to 30/06/2021) Sangui BioTech International Inc. achieved revenues from royalty income of USD 51,754. In the same period of the previous year the comparable revenue amounted to USD 21,176. Due to higher revenues of the wound spray Granulox, the resulting royalty income in the first nine month of the year was above the level of the same period of the previous year.

Operating expenses increased USD 11,731 or 8% to USD 162,793 during the first three quarters. As a result of the above factors, the nine month operating loss decreased USD 18,847 to USD 111,039. Due to the lower exchange rate of the US dollar to the EURO compared to the previous year's reporting date and the resulting increased exchange rate loss from the valuation of loans denominated in EURO, the loss of the nine month period increased by USD 24,513 to USD 151,923.

Sangui BioTech International, Inc. ("SGBI") is a holding company the shares of which are being traded on the OTCQB venture stage marketplace for early stage and developing U.S. and international companies (OTCQB: SGBI). Companies are current in their reporting and undergo an annual verification and management certification process. Sangui shares also trade on the OTC markets of Berlin and Hamburg-Hannover stock exchanges (symbol: SBH). Its purpose is to provide financing and access to the capital markets for the enterprises of the Sangui group. SanguiBioTech GmbH is a ninety percent subsidiary of Sangui BioTech International, Inc.

For more information please contact:
Sangui Biotech International, Inc.
Thomas Striepe
e-mail: info@sangui.de

Some of the statements contained in this news release discuss future expectations, contain projections of results of operation or financial condition or state other “forward-looking” information. These statements are subject to known and unknown risks, uncertainties, and other factors that could cause the actual results to differ materially from those contemplated by the statements. The forward-looking information is based on various factors and is derived using numerous assumptions.  Important factors that may cause actual results to differ from projections include, among many others, the ability of the Company to raise sufficient capital to meet operating requirements. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” and variations of such words and similar expressions are intended to identify such forward-looking statements. Unless required by law, the Company undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.